Associated equity: ReNeuron Group
ReNeuron is a UK biotech company developing allogeneic cell therapies. The first pivotal Phase IIb trial for CTX neural stem cells for chronic stroke disability is underway. Human retinal progenitor cells (hRPCs) are also being studied for RP (in Phase I/IIa).
ReNeuron Group — 4 videos in collection
ReNeuron is a UK biotech company developing allogeneic (off-the-shelf) novel stem cell therapies to address debilitating conditions with significant unmet clinical needs. Neural stem cell-based products, developed from an immortalised CTX single cell line, are in clinical studies: ReN001 in Phase II aimed at improving disability in ischaemic stroke patients and ReN009 in Phase I for critical limb ischaemia. ReN003, derived from human retinal progenitor cells, will enter a Phase I/II study for retinitis pigmentosa by H215.
CFO Michael Hunt outlines the company’s cell-based technology platforms and highlights the potential clinical data catalysts that investors should watch out for over the next 12-18 months. He also comments on the company’s solid financial position, which enables the development of its multiple products to their next valuation inflection points, with Neil Woodford of Woodford Investment Management now a cornerstone investor (19.9% stake).